Скачать с ютуб Treatment challenges in acral and mucosal melanoma в хорошем качестве

Treatment challenges in acral and mucosal melanoma

Yana Najjar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, describes the challenges in treating acral and mucosal melanoma, highlighting how current strategies largely mirror cutaneous melanoma approaches despite poorer outcomes. There are limited options post-progression on ipilimumab-nivolumab, but relatlimab-nivolumab and lifileucel has been used for advanced cases, though these are not always feasible. Emerging therapies in trials like ARTISTRY-6 (NCT04830124) and next-generation cellular and checkpoint therapies represent promising avenues to address these difficult-to-treat melanoma subtypes. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.